Today, Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and Russian Direct Investment Fund (RDIF) say study conducted at the National Institute for Infectious Diseases Lazzaro Spallanzani (Italy) shows Sputnik V can neutralize the Omicron (B.1.1.529) variant by inducing robust antibody response associated with high levels of protection.
It has demonstrated more than 2 times higher titers of virus neutralizing antibodies to the Omicron variant than 2 doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3 months after vaccination).
The study was conducted in the equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus neutralizing activity (VNA) against Wuhan variant.
